arrow
P

Praveen K. Bommareddy

Harvard University
H指数:24
被引数:2,927

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Initial results from an open-label phase 1b/2 study of RP1 oncolytic immunotherapy in solid organ transplant recipients with advanced cutaneous malignancies (ARTACUS)
2024-04-051
PRE
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
2023-07-119
OAAI
IGNYTE: AN OPEN-LABEL, MULTICENTER, PHASE 1/2 (PH 1/2) CLINICAL TRIAL OF RP1 ± NIVOLUMAB IN PATIENTS WITH ADVANCED SOLID TUMORS
2021-11-100
OA
A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]
2021-09-011
OA
CONSTRUCTION OF THE IMMUNE LANDSCAPE OF DURABLE RESPONSE TO CHECKPOINT BLOCKADE THERAPY BY INTEGRATING PUBLICLY AVAILABLE DATASETS
2020-04-150
OAAI
Intratumoral injection of the seasonal flu shot converts immunologically cold tumors to hot and serves as an immunotherapy for cancer

肿瘤内注射季节性流感疫苗将免疫冷肿瘤转化为热肿瘤,并作为癌症的免疫疗法

2019-12-30141
OAAI
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

DRD2拮抗剂ONC201在每周口服给药的晚期实体瘤患者中的安全性和增强的免疫刺激活性

2019-05-2253
OAAI